BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:BLC - FR0000035370 - Common Stock
26.05 EUR
-0.05 (-0.19%)
Overall BLC gets a fundamental rating of 4 out of 10. We evaluated BLC against 27 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of BLC while its profitability can be described as average. BLC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
BLC had positive earnings in the past year.
In the past year BLC had a positive cash flow from operations.
Of the past 5 years BLC 4 years were profitable.
Each year in the past 5 years BLC had a positive operating cash flow.
1.2 Ratios
BLC's Return On Assets of 0.08% is on the low side compared to the rest of the industry. BLC is outperformed by 85.19% of its industry peers.
BLC has a Return On Equity of 0.73%. This is amonst the worse of the industry: BLC underperforms 81.48% of its industry peers.
BLC has a Return On Invested Capital (6.40%) which is in line with its industry peers.
The Average Return On Invested Capital over the past 3 years for BLC is in line with the industry average of 6.98%.
The 3 year average ROIC (6.14%) for BLC is below the current ROIC(6.40%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.73% | ||
| ROIC | 6.4% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
1.3 Margins
The Profit Margin of BLC (0.11%) is worse than 85.19% of its industry peers.
In the last couple of years the Profit Margin of BLC has declined.
The Operating Margin of BLC (8.17%) is better than 62.96% of its industry peers.
BLC's Operating Margin has been stable in the last couple of years.
BLC has a better Gross Margin (67.80%) than 81.48% of its industry peers.
BLC's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.17% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
BLC has about the same amout of shares outstanding than it did 1 year ago.
BLC has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for BLC has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.40, we must say that BLC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BLC (1.40) is worse than 70.37% of its industry peers.
The Debt to FCF ratio of BLC is 12.90, which is on the high side as it means it would take BLC, 12.90 years of fcf income to pay off all of its debts.
BLC has a Debt to FCF ratio of 12.90. This is in the lower half of the industry: BLC underperforms 62.96% of its industry peers.
BLC has a Debt/Equity ratio of 5.29. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 5.29, BLC is not doing good in the industry: 92.59% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Altman-Z | 1.4 |
ROIC/WACC1.26
WACC5.08%
2.3 Liquidity
BLC has a Current Ratio of 1.38. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
BLC's Current ratio of 1.38 is fine compared to the rest of the industry. BLC outperforms 70.37% of its industry peers.
A Quick Ratio of 1.18 indicates that BLC should not have too much problems paying its short term obligations.
BLC has a better Quick ratio (1.18) than 74.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 158.33% over the past year.
Measured over the past years, BLC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.37% on average per year.
BLC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.35%.
The Revenue has been growing slightly by 5.12% on average over the past years.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
Based on estimates for the next years, BLC will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.96% on average per year.
The Revenue is expected to grow by 7.69% on average over the next years.
EPS Next Y41.62%
EPS Next 2Y16.22%
EPS Next 3Y15.96%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.49%
Revenue Next 5Y7.69%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BLC is valuated quite expensively with a Price/Earnings ratio of 372.14.
BLC's Price/Earnings ratio is rather expensive when compared to the industry. BLC is more expensive than 85.19% of the companies in the same industry.
BLC is valuated expensively when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 9.53 indicates a reasonable valuation of BLC.
BLC's Price/Forward Earnings ratio is rather cheap when compared to the industry. BLC is cheaper than 88.89% of the companies in the same industry.
BLC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.22.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 372.14 | ||
| Fwd PE | 9.53 |
4.2 Price Multiples
88.89% of the companies in the same industry are more expensive than BLC, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BLC is valued cheaper than 85.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.02 | ||
| EV/EBITDA | 5.74 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLC does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as BLC's earnings are expected to grow with 15.96% in the coming years.
PEG (NY)8.94
PEG (5Y)N/A
EPS Next 2Y16.22%
EPS Next 3Y15.96%
5. Dividend
5.1 Amount
No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (12/3/2025, 5:28:00 PM)
26.05
-0.05 (-0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.14%
Inst Owner ChangeN/A
Ins Owners1.58%
Ins Owner ChangeN/A
Market Cap191.99M
Revenue(TTM)491.18M
Net Income(TTM)528.00K
Analysts83.33
Price Target36.72 (40.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP107.77%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.84%
EPS NY rev (3m)-8.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2%
Revenue NY rev (3m)-14.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 372.14 | ||
| Fwd PE | 9.53 | ||
| P/S | 0.39 | ||
| P/FCF | 6.02 | ||
| P/OCF | 2.09 | ||
| P/B | 2.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.74 |
EPS(TTM)0.07
EY0.27%
EPS(NY)2.73
Fwd EY10.49%
FCF(TTM)4.32
FCFY16.6%
OCF(TTM)12.48
OCFY47.9%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)8.94
PEG (5Y)N/A
Graham Number3.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.73% | ||
| ROCE | 8.71% | ||
| ROIC | 6.4% | ||
| ROICexc | 6.78% | ||
| ROICexgc | 12.12% | ||
| OM | 8.17% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.49% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Debt/EBITDA | 3.79 | ||
| Cap/Depr | 99.07% | ||
| Cap/Sales | 12.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.25% | ||
| Profit Quality | 6036.93% | ||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z | 1.4 |
F-Score8
WACC5.08%
ROIC/WACC1.26
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y41.62%
EPS Next 2Y16.22%
EPS Next 3Y15.96%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.49%
Revenue Next 5Y7.69%
EBIT growth 1Y18.25%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year133.33%
EBIT Next 3Y39.49%
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
What is the valuation status for BLC stock?
ChartMill assigns a valuation rating of 5 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the valuation of BASTIDE LE CONFORT MEDICAL based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 372.14 and the Price/Book (PB) ratio is 2.66.
How sustainable is the dividend of BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 107.77%.